Compare Stocks: CRVS, CELC, RLAY, and ABCL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.70 +0.4%	$9.80	$2.74 ▼ $13.18	$3.89B	1.32	4.11 million shs	3.38 million shs
CELC Celcuity	$79.52 +0.2%	$88.66	$44.42 ▼ $151.02	$3.89B	0.19	842,211 shs	557,324 shs
CRVS Corvus Pharmaceuticals	$11.62 -1.5%	$13.76	$6.39 ▼ $26.95	$977.49M	0.87	1.10 million shs	1.10 million shs
RLAY Relay Therapeutics	$17.47 -1.5%	$19.18	$4.32 ▼ $21.27	$3.83B	1.69	3.44 million shs	2.98 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+0.55%	+2.42%	+72.09%	+166.25%
CELC Celcuity	0.00%	-1.35%	-14.71%	-20.44%	+47.31%
CRVS Corvus Pharmaceuticals	0.00%	-7.48%	-21.06%	-13.66%	+79.32%
RLAY Relay Therapeutics	0.00%	-7.27%	-10.04%	-5.87%	+286.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.70 +0.4%	$9.80	$2.74 ▼ $13.18	$3.89B	1.32	4.11 million shs	3.38 million shs
CELC Celcuity	$79.52 +0.2%	$88.66	$44.42 ▼ $151.02	$3.89B	0.19	842,211 shs	557,324 shs
CRVS Corvus Pharmaceuticals	$11.62 -1.5%	$13.76	$6.39 ▼ $26.95	$977.49M	0.87	1.10 million shs	1.10 million shs
RLAY Relay Therapeutics	$17.47 -1.5%	$19.18	$4.32 ▼ $21.27	$3.83B	1.69	3.44 million shs	2.98 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+0.55%	+2.42%	+72.09%	+166.25%
CELC Celcuity	0.00%	-1.35%	-14.71%	-20.44%	+47.31%
CRVS Corvus Pharmaceuticals	0.00%	-7.48%	-21.06%	-13.66%	+79.32%
RLAY Relay Therapeutics	0.00%	-7.27%	-10.04%	-5.87%	+286.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.63	Moderate Buy	$12.86	1.24% Upside
CELC Celcuity	2.83	Moderate Buy	$154.75	94.61% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	186.86% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	48.35% Upside

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ABCL AbCellera Biologics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$13.00
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$157.00
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/17/2026	CELC Celcuity	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$165.00 ➝ $175.00
8/17/2026	CELC Celcuity	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/17/2026	CELC Celcuity	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$177.00
8/14/2026	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00
8/14/2026	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$175.00 ➝ $150.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$66.17M	58.85	N/A	N/A	$3.23 per share	3.93
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	91.67	$0.73 per share	N/A
RLAY Relay Therapeutics	$10.35M	369.89	N/A	N/A	$3.27 per share	5.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)

Latest CRVS, CELC, RLAY, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
CELC Celcuity	6.04	8.93	8.93
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
RLAY Relay Therapeutics	N/A	18.27	18.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CELC Celcuity	63.33%
CRVS Corvus Pharmaceuticals	46.64%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
CELC Celcuity	13.33%
CRVS Corvus Pharmaceuticals	19.70%
RLAY Relay Therapeutics	5.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable

CRVS, CELC, RLAY, and ABCL Headlines

Recent News About These Companies

Relay Therapeutics (NASDAQ:RLAY) Shares Down 8.8% - What's Next?

September 23, 2026 | marketbeat.com

Relay Therapeutics stock holds near its Nasdaq quote

September 22, 2026 | ad-hoc-news.deA

Head to Head Survey: Relay Therapeutics (NASDAQ:RLAY) and I-Mab (NASDAQ:NBP)

September 22, 2026 | americanbankingnews.com

Bank of America Corp DE Invests $50.42 Million in Relay Therapeutics, Inc. $RLAY

September 21, 2026 | marketbeat.com

Relay Therapeutics stock consolidates after recent gains as investors watch pipeline progress

September 20, 2026 | ad-hoc-news.deA

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Squarepoint Ops LLC Has $1.74 Million Position in Relay Therapeutics, Inc. $RLAY

September 16, 2026 | marketbeat.com

Wellington Management Group LLP Has $2.94 Million Stock Position in Relay Therapeutics, Inc. $RLAY

September 11, 2026 | marketbeat.com

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

September 10, 2026 | seekingalpha.com

Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,530 Shares of Stock

September 10, 2026 | insidertrades.com

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 8,530 Shares of Stock

September 9, 2026 | marketbeat.com

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of Stock

September 9, 2026 | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) CEO Sanjiv Patel Sells 48,199 Shares of Stock

September 9, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Relay Therapeutics, Inc. $RLAY

September 9, 2026 | marketbeat.com

Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY

September 7, 2026 | marketbeat.com

Raiffeisen Bank International AG Cuts Stock Position in Relay Therapeutics, Inc. $RLAY

September 6, 2026 | marketbeat.com

Legal & General Group Plc Acquires New Shares in Relay Therapeutics, Inc. $RLAY

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $3.33 Million Stock Position in Relay Therapeutics, Inc. $RLAY

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Relay Therapeutics, Inc. $RLAY

September 3, 2026 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 3, 2026 | marketbeat.com

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

September 2, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.70 +0.05 (+0.40%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$12.79 +0.09 (+0.71%)

As of 09/25/2026 07:56 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Celcuity NASDAQ:CELC

$79.52 +0.15 (+0.19%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$79.56 +0.04 (+0.04%)

As of 09/25/2026 07:30 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corvus Pharmaceuticals NASDAQ:CRVS

$11.62 -0.18 (-1.53%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$11.64 +0.02 (+0.17%)

As of 09/25/2026 07:30 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Relay Therapeutics NASDAQ:RLAY

$17.47 -0.26 (-1.47%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$17.62 +0.15 (+0.85%)

As of 09/25/2026 07:58 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CELC, RLAY, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CELC, RLAY, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, CELC, RLAY, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, CELC, RLAY, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, CELC, RLAY, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, CELC, RLAY, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Relay Therapeutics NASDAQ:RLAY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools